Atopic Dermatitis Plasma

About Atopic Dermatitis Plasma

Atopic Dermatitis Plasma for Type 2 Inflammation and Skin Barrier Research

Atopic Dermatitis Plasma is collected from IRB-consented donors clinically diagnosed with atopic dermatitis, a chronic form of eczema, and processed within one day of collection to preserve cytokines, chemokines, proteins, and metabolites. Atopic dermatitis is an allergic, type 2-skewed inflammatory disease in which epidermal barrier dysfunction and a Th2-dominated immune response reinforce each other; it is not an autoantibody-driven condition. Plasma from these donors supports research into circulating type 2 mediators, barrier biology, and treatment response.

Why Plasma for Atopic Dermatitis Research

• The core cytokines of atopic dermatitis — IL-4, IL-13, IL-5 and IL-31 — are the direct targets of dupilumab, tralokinumab, nemolizumab and the JAK inhibitor class. Plasma is the accessible matrix for measuring the soluble output of that axis and for pharmacodynamic work.
• CCL17 (TARC) is among the best-replicated circulating correlates of atopic dermatitis severity, and CCL22, periostin and TSLP-associated markers are studied alongside it. All are measurable in plasma.
• Barrier dysfunction is central to the disease. Filaggrin loss-of-function variants are the strongest established genetic risk factor, and plasma from genotyped donors allows soluble inflammatory readouts to be interpreted against barrier genotype.
• Total IgE and eosinophil-associated mediators reflect the type 2 skew and the atopic comorbidity burden — asthma, allergic rhinitis and food allergy — that frequently accompanies atopic dermatitis.
• Plasma avoids the ex vivo platelet degranulation that occurs during clotting, which matters when measuring platelet-stored chemokines such as CXCL4 and CCL5 that would otherwise be artefactually elevated in serum.
• Plasma drawn alongside a skin punch biopsy or PBMCs from the same donor lets circulating mediators be tied to lesional tissue and to the responsible cell populations.

Donor Stratification Available

• Disease severity by EASI, SCORAD or Investigator Global Assessment where recorded
• Body surface area involvement and affected sites
• Total IgE level and blood eosinophil count where available
• Treatment status: topical-only, biologic-naive, on dupilumab or other type 2 biologic, on JAK inhibitor, on systemic immunosuppressant, or in washout
• Atopic comorbidity: asthma, allergic rhinitis, food allergy, or atopic dermatitis alone
• Age group, including paediatric and adult donors
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed atopic dermatitis donors
• Processed within one day of collection
• Anticoagulant selection available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified atopic dermatitis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Disease severity and treatment history where available
• Additional atopic dermatitis-specific metadata available on request
• Explore our Atopic Dermatitis Donor Network

Applications

• Type 2 cytokine and chemokine multiplex profiling, including CCL17/TARC
• Pharmacodynamic and target-engagement studies for IL-4R, IL-13 and IL-31 directed therapeutics
• Biomarker discovery and validation for disease severity and flare prediction
• Proteomic profiling of systemic type 2 inflammation
• Metabolomic and lipidomic studies of barrier lipid metabolism
• Itch pathway research focused on IL-31 and related mediators
• Assay development and validation using disease-state plasma as a clinically relevant matrix
• Comparative profiling of atopic dermatitis against psoriasis and other inflammatory skin disease

Other Atopic Dermatitis Specimen Types

• Atopic Dermatitis Serum
• Atopic Dermatitis Whole Blood
• Atopic Dermatitis PBMC
• Atopic Dermatitis Leukopak
• Atopic Dermatitis Skin Punch Biopsy
• Atopic Dermatitis Bulk Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Atopic dermatitis plasma is available in standard and custom volumes. For pricing, availability, or to discuss a severity-stratified cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse plasma across all disease states and healthy donors, visit our human plasma page.